Biorce Closes $52.5 Million Series A to Accelerate International Expansion and Lead the Transformation of Clinical Trials through AI

Biorce, a Barcelona-based health AI company specialized in applying artificial intelligence to the design and execution of clinical trials, led by Pedro Coelho, Clara Bernardes, José Faria, Diogo Pisoeiro, and others, has raised $52.5 million in a Series A round. The financing includes new investment from DST Global Partners, with existing investors Norrsken VC and YZR Capital increasing their participation, alongside participation from Mustard Seed Maze and Endeavor Catalyst. The round also includes prominent angel investors such as Nik Storonsky (Revolut), Arthur Mensch (Mistral AI), Paulo Rosado (OutSystems), Albert Nieto (Seedtag), Stef Van Grieken (Cradle), and Alex Berriche (Fleet), and Phil Teixeira da Mota, among others.  

The investment underscores Biorce’s rapid growth and its emergence as a highly credible player in the transformation of clinical research. Over a 12-month period, the company secured €8.5 million in seed funding, €3.5 million in November 2024, followed by a €5 million extension from Norrsken VC in summer 2025, culminating in a $52.5 million Series A round. The close succession of these financings reflects strong investor confidence in Biorce’s technology, execution, and long-term vision.

With this round, total funding now exceeds $60 million. The company closed the previous year with revenue approximately 200% above target.

Clinical trials management accounts for an estimated $120 billion in annual global spend. Biorce is developing AI infrastructure to help establish a new industry standard for clinical trial design and execution, with Aika at its core.

Under traditional models, protocol amendments often pause patient recruitment for around six weeks and add €500,000 to €1 million in costs, creating billions in annual inefficiencies. These delays frequently stem from difficulties in clearly justifying design decisions to regulators such as the FDA and EMA, triggering reviews and additional amendments.

Aika addresses these challenges through a data-driven, scientific platform built on insights from one million clinical trials. By anticipating risks and reducing errors, the system aims to eliminate costly amendments and accelerate therapy development by up to 50%, enabling faster, higher-quality trial design without compromising scientific rigor or patient safety.

The $52 million round reflects both the scale of inefficiencies in clinical trials and strong market confidence in Biorce’s vision. By addressing delays that cost time, capital, and lives, the company aims to make trials faster, more reliable, and more accessible, accelerating patient access to new treatments. The rapid pace of fundraising since July 2025 underscores validation of the technology, team, and potential impact.

Strong conviction in the team’s ability to build a global AI platform for clinical trials has been reinforced by execution that has exceeded expectations. Growing international demand demonstrates the platform’s impact in reducing timelines and costs while accelerating patient access to new treatments. The continued investment supports expansion into the U.S. and reinforces the company’s trajectory toward becoming a category-defining leader in clinical research.

Early investment in Biorce in 2024 was driven by confidence in the company’s vision to transform clinical trial design and execution. The urgent market need for a solution like Aika reinforced this conviction, highlighting a significant opportunity in PharmaTech. Rapid progress since the initial investment strengthens confidence in Biorce’s potential to become a global leader in the space.

Biorce plans to expand its team to 250 employees by the end of 2026 and is establishing a development and R&D hub in Austin, Texas, enhancing its U.S. presence and proximity to leading pharmaceutical and biotech ecosystems. The company is also relocating to larger offices in Barcelona, formerly AstraZeneca’s headquarters, to support its next phase of growth.

In early 2026, focus will be on enhancing Aika’s protocol intelligence and introducing modules for contract management, negotiation, budget planning, and operational execution. Already deployed across multiple therapeutic areas, including oncology, neurology, and rare diseases, Aika’s therapy-agnostic platform enables scalable AI-driven trial design and management, establishing a new industry standard.